Attenuated ΔguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses

Clinical Immunology

Volumn 92, Issue 1, 1999, Pages 76-89

  Pasetti, Marcela F ^a   Anderson, Richard J ^a   Noriega, Fernando R ^a   Levine, Myron M ^a   Sztein, Marcelo B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

DNA immunization; Live vectors; Salmonella typhi; Vaccines

Indexed keywords

SALMONELLOSIS VACCINE; BACTERIAL ANTIGEN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CYTOKINE; LIVE VACCINE; RECOMBINANT PROTEIN;

ANTIBODY TITER; ARTICLE; BACTERIAL MUTATION; EXPRESSION VECTOR; GENE DELETION; GENE TARGETING; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SALMONELLA TYPHI; STRAIN DIFFERENCE; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; BLOOD; CELL DIVISION; CYTOLOGY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LYMPH NODE; MOUSE; SPLEEN;

SALMONELLA TYPHI;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CELL DIVISION; CYTOKINES; LYMPH NODES; MICE; RECOMBINANT PROTEINS; SALMONELLA TYPHI; SPLEEN; VACCINES, ATTENUATED;

EID: 0032588738     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4733     Document Type: Article

References (51)

1. Levine M. M., Hone D., Heppner D. G., Noriega F., Sriwathana B. Attenuated Salmonella as carriers for the expression of foreign antigens. Microecol. Ther. 19:1990;23-32.
2. Chatfield S. N., Charles I. G., Makoff A. J., Oxer M. D., Dougan G., Pickard D., Slater D., Fairweather N. F. Use of the nirB promoter to direct stable expression of heterologous antigens in Salmonella vaccine strains: Development of a single dose oral tetanus vaccine. Biotechnology. 10:1992;888-892.
3. Gonzalez C., Hone D., Noriega F. R., Tacket C. O., Davis J. R., Losonsky G., Nataro J. P., Hoffman S., Malik A., Nardin E. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: Strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169:1994;927-931.
4. Schodel F., Curtiss R. Salmonellae as oral vaccine carriers. Dev. Biol. Stand. 84:1995;245-253.
5. Everest P., Griffiths P., Dougan G. Live Salmonella vaccines as a route towards oral immunisation. Biologicals. 23:1995;119-124.
6. Fouts T. R., Tuskan R. G., Chada S., Hone D. M., Lewis G. K. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. Vaccine. 13:1995;1697-1705.
7. Gomez-Duarte O. G., Galen J., Chatfield S. N., Rappuoli R., Eidels L., Levine M. M. Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain. Vaccine. 13:1995;1596-1602.
8. Levine M. M., Galen J., Barry E., Noriega F., Chatfield S., Sztein M., Dougan G., Tacket C. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J. Biotechnol. 44:1996;193-196.
9. Noriega F. R., Losonsky G., Lauderbaugh C., Liao F. M., Wang J. Y., Levine M. M. Engineered ΔguaB-A ΔvirG Shigella flexneri 2a strain CVD 1205: Construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect. Immun. 64:1996;3055-3061.
10. Anderson R., Dougan G., Roberts M. Delivery of the Pertactin/P.69 polypeptide of Bordetella pertussis using an attenuated Salmonella typhimurium vaccine strain: Expression levels and immune response. Vaccine. 14:1996;1384-1390.
11. Barry E. M., Gomez-Duarte O., Chatfield S., Rappuoli R., Pizza M., Losonsky G., Galen J., Levine M. M. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect. Immun. 64:1996;4172-4181.
12. Harrison J. A., Villarreal-Ramos B., Mastroeni P., Demarco d. H., Hormaeche C. E. Correlates of protection induced by live Aro-Salmonella typhimurium vaccines in the murine typhoid model. Immunology. 90:1997;618-625.
13. Levine M. M., Galen J., Barry E., Noriega F., Tacket C., Sztein M., Chatfield S., Dougan G., Losonsky G., Kotloff K. Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors. Behring. Inst. Mitt. 1997;120-123.
14. Galen J. E., Gomez-Duarte O. G., Losonsky G. A., Halpern J. L., Lauderbaugh C. S., Kaintuck S., Reymann M. K., Levine M. M. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine. 15:1997;700-708.
15. Comoy E. E., Vendeville C., Capron A., Thyphronitis G. Infection with Salmonella typhimurium modulates the immune response to Schistosoma mansoni glutathione-S-transferase. Infect. Immun. 65:1997;3261-3266.
16. Dunstan S. J., Simmons C. P., Strugnell R. A. Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Infect. Immun. 66:1998;732-740.
17. Noriega F. R., Losonsky G., Wang J. Y., Formal S. B., Levine M. M. Further characterization of ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect. Immun. 64:1996;23-27.
18. Fynan E. F., Webster R. G., Fuller D. H., Haynes J. R., Santoro J. C., Robinson H. L. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA. 90:1993;11478-11482.
19. Tang D. C., DeVit M., Johnston S. A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:1992;152-154.
20. Davis H. L., Michel M. L., Whalen R. G. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2:1993;1847-1851.
21. Donnelly J. J., Ulmer J. B., Shiver J. W., Liu M. A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
22. Hone D. M., Harris A. M., Chatfield S., Dougan G., Levine M. M. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine. 9:1991;810-816.
23. Anderson, R. J, Pasetti, M. F, Sztein, M. B, Levine, M. M, and, Noriega, F, ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. Submitted, 1999.
24. Courvalin P., Goussard S., Grillot-Courvalin C. Gene transfer from bacteria to mammalian cells. C. R. Acad. Sci. III. 318:1995;1207-1212.
25. Darji A., Guzman C. A., Gerstel B., Wachholz P., Timmis K. N., Wehland J., Chakraborty T., Weiss S. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 91:1997;765-775.
26. Sizemore D. R., Branstrom A. A., Sadoff J. C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science. 270:1995;299-302.
27. Fennelly G. J., Khan S. A., Abadi M. A., Wild T. F., Bloom B. R. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J. Immunol. 162:1999;1603-1610.
28. Noriega, F, Pasetti, M. F, Wang, J. Y, Anderson, R. J, Sztein, M. B, and, Levine, M. M, Construction and characterization of attenuated ΔguaBA Salmonella typhi strain CVD 915. Submitted for publication, 1999.
29. Anderson R., Gao X. M., Papakonstantinopoulou A., Roberts M., Dougan G. Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Infect. Immun. 64:1996;3168-3173.
30. Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1987;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
31. Wyant T. L., Tanner M. K., Sztein M. B. Potent immunoregulatory effects of Salmonella typhi flagella on antigenic stimulation of human peripheral blood mononuclear cells. Infect. Immun. 67:1999;1338-1346.
32. Levine M. M., Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet. 351:1998;1375-1376.
33. Tighe H., Corr M., Roman M., Raz E. Gene vaccination: Plasmid DNA is more than just a blueprint. Immunol. Today. 19:1998;89-97.
34. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
35. Pickett T. E., Pasetti M. F., Tanner M. K., Sztein M. B., Levine M. M. In vivo localization of Salmonella typhi in the intranasal mouse model of typhoid vaccine immunogenicity. Am. J. Trop. Med. Hygiene. 59:1998;363.
36. Pasetti M. F., Tanner M. K., Pickett T. E., Levine M. M., Sztein M. B. Lymphoid populations involved in the early stages of the immune response following intranasal immunization with S. typhi vaccine strains in mice. Am. J. Trop. Med. Hygiene. 59:1998;362.
37. Kaufmann S. H. Immunity to intracellular bacteria. Paul W. E. Fundamental Immunology. 1999;1335-1371 Lippincott-Raven, Philadelphia.
38. Del Prete G. The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int. Rev. Immunol. 16:1998;427-455.
39. Mosmann T. R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:1996;138-146.
40. Sztein M. B., Mitchell G. Recent Advances in Immunology: Impact on vaccine development. Levine M. M., Woodrow G. C., Kaper J. B., Cobon G. S. New Generation Vaccines. 1997;99-125 Dekker, New York.
41. Snapper C. M., Finkelman F. D. Immunoglobulins and class switching. Paul W. E. Fundamental Immunology. 1999;831-861 Lippincott-Raven, Philadelphia.
42. Sztein M. B., Tanner M., Polotsky Y., Orenstein J. M., Levine M. M. Cytotoxic T Lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J. Immunol. 155:1995;3987-3993.
43. Sztein M. B., Wasserman S. S., Tacket C. O., Edelman R., Hone D., Lindberg A. A., Levine M. M. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 170:1994;1508-1517.
44. Muotiala A., Makela P. H. The role of IFN-gamma in murine Salmonella typhimurium infection. Microb. Pathog. 8:1990;135-141.
45. VanCott J. L., Kobayashi T., Yamamoto M., Pillai S., McGhee J. R., Kiyono H. Induction of pneumococcal polysaccharide-specific mucosal immune responses by oral immunization. Vaccine. 14:1996;392-398.
46. Mastroeni P., Harrison J. A., Chabalgoity J. A., Hormaeche C. E. Effect of interleukin 12 neutralization on host resistance and gamma interferon production in mouse typhoid. Infect. Immun. 64:1996;189-196.
47. Ramarathinam L., Shaban R. A., Niesel D. W., Klimpel G. R. Interferon gamma (IFN-gamma) production by gut-associated lymphoid tissue and spleen following oral Salmonella typhimurium challenge. Microb. Pathog. 11:1991;347-356.
48. Mastroeni P., Harrison J. A., Robinson J. H., Clare S., Khan S., Maskell D. J., Dougan G., Hormaeche C. E. Interleukin-12 is required for control of the growth of attenuated aromatic-compound-dependent salmonellae in BALB/c mice: Role of gamma interferon and macrophage activation. Infect. Immun. 66:1998;4767-4776.
49. Skeen M. J., Miller M. A., Shinnick T. M., Ziegler H. K. Regulation of murine macrophage IL-12 production. J. Immunol. 156:1996;1196-1206.
50. Chabalgoity J. A., Khan C. M., Nash A. A., Hormaeche C. E. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol. Microbiol. 19:1996;791-801.
51. Gonzalez C. R., Noriega F. R., Huerta S., Santiago A., Vega M., Paniagua J., Ortiz-Navarrete V., Isibasi A., Levine M. M. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana. Vaccine. 16:1998;1043-1052.